An Open-label, Multicenter, Non-randomized, Dose Escalation Phase 1 Trial to Evaluate Safety and Tolerability of INCSHR01210 in Subjects With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2017
At a glance
- Drugs INCSHR 1210 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 26 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 16 Sep 2016 Planned End Date changed from 1 Dec 2016 to 1 Aug 2018.
- 16 Sep 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Dec 2017.